7 Jan
2021

Surprise change to FDA Purple Book creates risks and opportunities for biosimilar producers

Reforms to the US’s biosimilars patent litigation create dangers as well as benefits for those seeking to market imitation biologics

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth